Full story
FDA Updates Menopause Therapy Warnings
The FDA is removing long-standing black box warnings about cardiovascular disease, breast cancer, and dementia from more than 20 hormone therapies for menopause.
“The FDA has announced it will ask drug companies to remove black box warnings from hormone therapies used to treat menopause symptoms.”
These warnings had been in place for decades, based on early-2000s interpretations of the Women’s Health Initiative.
Officials describe the change as a correction of misinterpretations that previously discouraged the use of these therapies.
However, the agency is keeping a boxed warning for endometrial cancer on systemic estrogen-only products.
The FDA and its supporters believe that clearer labels will help appropriate candidates, especially women under 60 or within 10 years of menopause, consider therapy without fear.
Several news outlets also highlight companion approvals of a generic Premarin and a non-hormonal hot-flash drug as part of a broader update in menopause care.
Updated Insights on Hormone Therapy Risks
Multiple sources report that reanalysis shows risk varies by age and timing, with fewer risks when hormone therapy is started near menopause.
Trade and local outlets emphasize correcting misconceptions from the WHI era.
Some caution against overstating the benefits of hormone therapy.
Analyses cited by Spectrum News NY1 find no increased heart risk among women in their 50s using estrogen but higher risks in older users.
ABC11 and Pharmacy Times similarly stress starting therapy before age 60 or within 10 years of menopause.
Asian and trade outlets argue that the original risks were exaggerated due to older study populations.
AJMC notes that labels will remove the 'lowest dose, shortest duration' language.
Some experts warn that the benefits of hormone therapy may be overstated.
Estrogen Therapy Labeling Updates
Multiple outlets emphasize that the boxed warning about endometrial cancer remains for systemic estrogen-only therapies.
“warnings about endometrial cancer will remain for systemic estrogen-alone products.”
Labeling will better distinguish systemic treatments from low-dose local vaginal estrogen.
Reports note distinct labeling for creams and rings.
There is an emphasis on the need for individualized decisions regarding these therapies.
Some experts highlight local vaginal estrogen as very safe.
Debate Over FDA Decision Process
The decision-making process has sparked debate.
Several reports indicate that the FDA bypassed a formal advisory committee.
This action has fueled criticism regarding transparency and potential conflicts.
Other sources emphasize that a comprehensive scientific review was conducted.
There is also support from professional societies for the decision.
Coverage includes calls for greater scrutiny of the process.
Statements from ACOG highlight the importance of individualized decisions.
Menopause Care Developments
Several outlets frame the move as part of a broader effort to modernize menopause care, expand access, and spur new options.
“The FDA also approved a generic version of Premarin and a non-hormonal treatment for hot flashes.”
Mainstream and trade coverage note approvals of a generic Premarin and a non-hormonal therapy.
Public radio reports say information will be expanded instead of using black box warnings.
National reporting points to state-level policy momentum.
Some business-focused coverage highlights commercial growth.
Public media and NPR emphasize the need for informed, individualized decisions despite the change.